中国普外基础与临床杂志

中国普外基础与临床杂志

胃间质瘤患者术前 C 反应蛋白/白蛋白比值与 NIH 分级相关性的研究

查看全文

目的 探讨胃间质瘤患者术前 C 反应蛋白(CRP)/白蛋白(Albumin)比值(CAR)与美国国立卫生研究院(NIH)的关系。 方法 回顾性收集 2010 年 2 月至 2017 年 12 月期间昆明医科大学第一附属医院收治的 108 例胃间质瘤患者的临床资料,以 CAR 的中位数为临界值,将患者分为高 CAR 值组(CAR>0.048)和低 CAR 值组(CAR≤0.048)。观察比较高、低 CAR 组的一般临床病理学特征及生存状态。 结果 高 CAR 组及低 CAR 组患者的肿瘤直径、核分裂象和 NIH 分级比较差异均有统计学意义(P<0.05),与低 CAR 组相比,高 CAR 组的肿瘤直径更大、核分裂象更高,NIH 分级越高。生存分析结果显示:低 CAR 组患者的预后较高 CAR 组更好(χ2=15.152,P<0.001)。 结论 CAR 与胃间质瘤的肿瘤直径、核分裂象和 NIH 分级密切相关,可作为评估胃间质瘤恶性程度的指标,有望在临床上作为 NIH 危险度分级评估及预后的重要参考因素。

Objective To investigate the relationship between preoperative C-reactive protein (CRP)/albumin ratio (CAR) and National Institutes of Health (NIH) risk classification in patients with gastric stromal tumors. Method Clinical data of 108 patients with gastric stromal tumors admitted to the First Affiliated Hospital of Kunming Medical University from October 2011 to December 2017 were retrospectively collected. With the median of CAR as the critical value, patients were divided into high CAR group (CAR>0.048) and low CAR group (CAR≤0.048). Then observed the general clinicopathological characteristics and survival status of patients with higher and lower CAR value. Results There were significant differences in NIH classification, tumor diameter, and mitosis between the high CAR group and low CAR groups (P<0.05). Compared with the low CAR group, the tumors in the high CAR group had larger diameter, higher mitotic figure, and higher NIH grade. Survival analysis showed that the prognosis of low CAR group was better than that of high CAR group (χ2=15.152, P<0.001). Conclusions CAR is closely related to the malignant index and NIH risk classification of gastric stromal tumors. It can be used as an index for evaluating the malignant degree of gastric stromal tumors, and it is expected to be an important reference factor for clinical NIH risk classification and prognosis.

关键词: 胃间质瘤; C 反应蛋白/白蛋白比值; 美国国立卫生研究院分级

Key words: gastric stromal tumor; CRP/albumin ratio; National Institutes of Health risk classification

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 1983, 7(6): 507-519.
2. Blay JY, Shen L, Kang YK, et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol, 2015, 16(5): 550-560.
3. Cassier PA, Ducimetière F, Lurkin A, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer, 2010, 103(2): 165-170.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Gastroenterol Clin North Am, 2013, 42(2): 399-415.
5. 谭至柔, 黄雪, 张瑜红. 46例胃间质瘤的临床分析. 中国现代医学杂志, 2011, 21(33): 4186-4187, 4191.
6. Pisters PW, Blanke CD, von Mehren M, et al. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Ann Oncol, 2011, 22(11): 2523-2529.
7. Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol, 2016, 40: 39-46.
8. Wang M, Xu J, Zhang Y, et al. Gastrointestinal stromal tumor: 15-years’ experience in a single center. BMC Surg, 2014, 14: 93.
9. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int, 2015, 65(1): 9-18.
10. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA, 2012, 307(12): 1265-1272.
11. Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol, 2016, 34(3): 244-250.
12. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008, 39(10): 1411-1419.
13. 尹晓南, 汤苏敏, 尹源, 等. 胃肠间质瘤患者术前PLR、d-NLR值与预后的关系. 四川大学学报(医学版), 2017, 48(2): 239-243, 275.
14. 胡根, 李威, 邵国益, 等. 术前血小板和淋巴细胞比值对胃间质瘤患者预后的预测价值. 肿瘤防治研究, 2018, 45(7): 479-482.
15. 金鑫, 冯利, 李福广, 等. 血清中性粒细胞/淋巴细胞比值与胃肠间质瘤患者预后的关系及其临床意义. 中国普外基础与临床杂志, 2013, 20(8): 910-914.
16. Kudou K, Saeki H, Nakashima Y, et al. C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. J Gastroenterol Hepatol, 2019, 34(2): 355-363.
17. Liu X, Sun X, Liu J, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol, 2015, 8(4): 339-345.
18. Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac J Clin Oncol, 2018, 14(6): 402-409.
19. Toiyama Y, Shimura T, Yasuda H, et al. Clinical burden of C-reactive protein/albumin ratio before curative surgery for patients with gastric cancer. Anticancer Res, 2016, 36(12): 6491-6498.
20. 刘恒昌, 陈羽佳, 许永飞, 等. 术前C反应蛋白与白蛋白比值对胃癌患者预后的影响. 中国实验诊断学, 2018, 22(1): 27-29.
21. 乔乐乐, 王公平, 周博, 等. 胃癌患者术前CRP/Alb比与淋巴结转移相关性的研究. 中国肿瘤临床, 2017, 44(5): 210-213.
22. Morris-Stiff G, Gomez D, Prasad KR. C-reactive protein in liver cancer surgery. Eur J Surg Oncol, 2008, 34(7): 727-729.
23. Du J, Hu W, Yang C, et al. C-reactive protein is associated with the development of tongue squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai), 2018, 50(3): 238-245.
24. Fiala O, Hosek P, Pesek M, et al. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Neoplasma, 2017, 64(4): 605-610.
25. Frydenberg H, Thune I, Lofterød T, et al. Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res Treat, 2016, 155(2): 345-354.
26. Kim ES, Kim SY, Koh M, et al. C-reactive protein binds to integrin α2 and Fcγ receptor Ⅰ, leading to breast cell adhesion and breast cancer progression. Oncogene, 2018, 37(1): 28-38.
27. Heneghan HM, Zaborowski A, Fanning M, et al. Prospective study of malabsorption and malnutrition after esophageal and gastric cancer surgery. Ann Surg, 2015, 262(5): 803-807.
28. Ryan AM, Power DG, Daly L, et al. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc, 2016, 75(2): 199-211.
29. Fairclough E, Cairns E, Hamilton J, et al. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond), 2009, 9(1): 30-33.